Akcea Therapeutics (AKCA) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
February 26, 2019 4:06 PM ESTTEGSEDI (inotersen) commercially available in United States, European Union & Canada
Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million
Conference Call Webcast Tuesday, February 26, 4:30 p.m. ET at www.akceatx.comÂ
BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing... More
